Nature Reviews Drug Discovery contents September 2017 Volume 16 Number 9 pp 587-661

If you are unable to see the message below, click here to view.
 

Advertisement
Better visualize, analyze, and phenotype immune cells in situ in FFPE tissue sections and TMAs  Vectra Polaris™ quantitative pathology imaging system from PerkinElmer provides unparalleled speed and performance for extracting proteomic and morphometric information from tissue sections with whole slide, brightfield, fluorescence and powerful multispectral imaging.  Learn More
TABLE OF CONTENTS
September 2017 Volume 16 Number 9		Advertisement
2016 2-year Impact Factor 57.000 Journal Metrics 2-year Median 38	In this issue Comment News and Analysis Research Highlights Reviews   Also this month  Featured article: The antifungal pipeline: a reality check John R. Perfect	Genomics has met its match! MAKE MORE MEANINGFUL CONNECTIONS A powerful first-line phenotyping technology delivering a readout of the molecular phenotype and all its influences, both genetic and non-genetic. See how genomics and metabolomics are breaking through together.
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Technical Paper: Streamline Production of Complex Proteins Producing high quality, functional proteins in a rapid and cost-effective manner can be challenging when dealing with complex or difficult-to-express proteins, particularly if cGMP-compliance is needed. Find out how implementing the right expression platform can transform your efforts. View Now
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Reviews Chemistry is an online-only journal that provides both an introduction to chemists embarking on a new topic of investigation and thought-provoking, in-depth sections for the expert. The journal also publishes regular columns which focus on the teaching of chemistry and on the translation of research into business opportunities. EXPLORE THE JOURNAL NOW
Advertisement
An interdisciplinary journal dedicated to publishing high-quality open research relevant to all aspects of schizophrenia and psychosis. Explore the benefits of submitting your next research article.
Comment: Bridging the translational innovation gap through good biomarker practice Alain J. van Gool, Florence Bietrix, Eric Caldenhoven, Kurt Zatloukal, Andreas Scherer, Jan-Eric Litton, Gerrit Meijer, Niklas Blomberg, Andy Smith, Barend Mons, Jaap Heringa, Wim-Jan Koot, Martin J. Smit, Marian Hajduch, Ton Rijnders & Anton Ussi p587 | doi:10.1038/nrd.2017.72 Few biomarkers progress from discovery to become validated tools or diagnostics. To bridge this gap, three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — are paving the way to developing and sharing best practices for biomarker validation. Full Text | PDF
NEWS AND ANALYSIS		Top
Synthetic lethality screens point the way to new cancer drug targets Asher Mullard p589 | doi:10.1038/nrd.2017.165 A resurgence in synthetic lethality screening, enabled by CRISPR gene editing, is unlocking targeted drugs for patients with cancerous loss-of-function mutations. PDF
FDA OKs first in vitro route to expanded approval Katie Kingwell p591 | doi:10.1038/nrd.2017.140 In vitro data can be used to accelerate the approval of drugs that target specific disease-causing mutations for additional subpopulations of patients with rare diseases such as cystic fibrosis. PDF
NEWS IN BRIEF FDA approves first-in-class cancer metabolism drug Asher Mullard p593 | doi:10.1038/nrd.2017.174 PDF
NEWS IN BRIEF Diabetes drug shows promise in Parkinson disease Asher Mullard p593 | doi:10.1038/nrd.2017.175 PDF
NEWS IN BRIEF FDA rejects first-in-class osteoporosis drug Asher Mullard p593 | doi:10.1038/nrd.2017.176 PDF
BIOBUSINESS BRIEFS Regulatory watch: Structural and procedural characteristics of international regulatory authorities Anand B. Jain, Annette Mollet & Thomas D. Szucs p594 | doi:10.1038/nrd.2017.135 PDF
Deal watch: IL-2 focus switches to stimulating Tregs Megan Cully p595 | doi:10.1038/nrd.2017.171 PDF
AN AUDIENCE WITH Nigel Blackburn p596 | doi:10.1038/nrd.2017.172 Nigel Blackburn, Director of drug development at CRUK, discusses the charity's changing approach to bolstering the cancer drug pipeline. PDF
FROM THE ANALYST'S COUCH What is the right amount to spend on biopharma R&D? Michael S. Ringel p597 | doi:10.1038/nrd.2017.114 This analysis investigates whether some companies may be negatively affecting their overall commercial success by aiming to maintain steady earnings per share growth and/or a target ratio of R&D spending to sales. PDF
RESEARCH HIGHLIGHTS   Top Cancer immunotherapy: Searching in the immune checkpoint black box p599 | doi:10.1038/nrd.2017.163 PDF Antibacterial agents: New routes to tuberculosis treatment p600 | doi:10.1038/nrd.2017.156 PDF Inflammatory diseases: An IL-9 solution to inflammation resolution p600 | doi:10.1038/nrd.2017.164 PDF Biotechnology: CRISPR-Cas becoming more human p601 | doi:10.1038/nrd.2017.167 PDF Cancer: Ironing it out p602 | doi:10.1038/nrd.2017.168 PDF   IN BRIEF Anticancer agents: Fighting resistance | Immunotherapy: CAR T cells in glioblastoma | Systems medicine: Understanding wellness and disease | Cancer: Inhibiting ROCK in neuroblastoma PDF Nature Reviews Drug Discovery JOBS of the week Faculty Position in Cancer Immunology Penn State College of Medicine / Penn State Milton S. Hershey Medical Center Head of Human Therapeutics Wisconsin Alumni Research Foundation (WARF) Scientist / Post-doc in CAR-T Cell Engineering & Immunotherapy (M / F) University Hospital of Wuerzburg Director / Senior Director, Pathology, Genentech Research Genentech, Inc. Recruitment Program of Global Experts (Thousand Talents Program) Sun Yat-sen University More Science jobs from Nature Reviews Drug Discovery EVENT Drug Discovery and Development 02.10.17 Tokyo, Japan More science events from
Advertisement
World Congress on Animal Models in Drug Discovery and Development Charles River has proudly partnered with the EBD Group to provide the scientific program for this year's BioPharm America Conference™. Be a part of this two-day conference that aims to bridge the gap between drug discovery and clinical application. Register now>>
REVIEWS		Top
The antifungal pipeline: a reality check John R. Perfect p603 | doi:10.1038/nrd.2017.46 Invasive fungal infections are a major medical concern, particularly in immunocompromised patients. In this Review, Perfect discusses the antifungal pipeline, including advances in the currently used drug classes, novel molecular targets, drugs that could be repurposed from other areas and the use of immune-directed therapies. Abstract | Full Text | PDF
Remyelination therapies: a new direction and challenge in multiple sclerosis Jason R. Plemel, Wei-Qiao Liu & V. Wee Yong p617 | doi:10.1038/nrd.2017.115 Restoring damaged myelin could reverse the neurological effects observed in patients with multiple sclerosis. In this Review, Yong and colleagues discuss the progress made in remyelinating therapies, including novel and potential repurposed agents, and highlight the challenges in preclinical and clinical development for such drugs. Abstract | Full Text | PDF
Therapeutic targeting of the angiopoietin-TIE pathway Pipsa Saharinen, Lauri Eklund & Kari Alitalo p635 | doi:10.1038/nrd.2016.278 The angiopoietin (ANG)-TIE growth factor receptor pathway regulates pathological vascular remodelling during inflammation, tumour angiogenesis and metastasis. It has become an attractive pharmacological target for oncological and ophthalmological indications, as well as sepsis, diabetic vasculopathies, organ transplantation and atherosclerosis. Here, Alitalo and colleagues provide an overview of the biology of the ANG-TIE pathway and discuss the development of therapeutics that target it. Abstract | Full Text | PDF
Corrigendum: Opportunities for therapeutic antibodies directed at G-protein-coupled receptors Catherine J. Hutchings, Markus Koglin, William C. Olson & Fiona H. Marshall p661 | doi:10.1038/nrd.2017.173 Full Text | PDF
Advertisement
nature.com webcasts Nature Research Custom presents a webcast on: HCS for Predictive Toxicology and in vitro Pathology Using Simple 3D Microtissues Date: Wednesday, September 6, 2017 Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST Duration: 60 minutes with an opportunity to ask questions during the live broadcast!  Register for FREE Sponsored by:  PerkinElmer
Advertisement
Free Naturejobs Career Expo London - registration is now open  The 11th annual Naturejobs Career Expo will be held in London on October 4, 2017. Join us for your chance to network with leading global employers, receive one-to-one CV checking, attend free talks and workshops, learn how to enhance your employability and lots more.  Register FREE today!
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.